KDventures AB Class B
0.02
EUR
0.00
(0.00%)
KDventures AB Class B
GETTEX:2I9
(Gettex)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Karolinska Development AB (publ) is a Nordic life science investment company focused on identifying, investing in, and developing breakthrough medical innovations originating primarily from the Nordic region. The company manages a diverse portfolio of life science companies primarily engaged in pharmaceutical drug development and medical devices. Its core offerings include investments and active development in companies that advance innovative treatment candidates and medical technologies targeting life-threatening or serious debilitating diseases. The portfolio includes drug candidates in various phases of clinical trials and medical device products in the commercial phase. Karolinska Development leverages partnerships with leading universities, notably Karolinska Institutet, and collaborates with experienced management teams and co-investors, including international specialist investors. The company was founded in 2003 and is headquartered in Stockholm, Sweden. Recent major developments include a proposed rights issue of approximately SEK 203 million intended to finance ongoing development of its existing portfolio companies, new investments, and general corporate purposes. Notable portfolio companies, such as Dilafor and BOOST Pharma, are preparing to initiate phase 3 clinical trials, potentially enhancing licensing or divestment opportunities. The company also plans a name change to KDventures AB, reflecting a strategic repositioning and minor adjustments to its business scope. Additionally, Karolinska Development continues to focus on expanding its portfolio and progressing key clinical milestones, with several portfolio companies expected to release significant trial data during 2025–2026. The company maintains strategic guarantee commitments from external investors to support the rights issue, emphasizing its drive to maximize shareholder value through clinical advancements and commercialization opportunities. Karolinska Development operates within the healthcare and life sciences industry, specifically focusing on venture investment and company building in pharmaceutical and medical technology sectors. Its target markets are primarily innovations originating in the Nordic region with global commercial potential, supporting the development from early research stages through clinical trials to market launch or licensing. The company currently manages a portfolio consisting of approximately eleven investments, which include pharmaceutical drug development projects and medical device companies in various stages of commercialization. Karolinska Development holds strategic influence over its portfolio companies to maximize value creation and leverages its scientific and investor networks for scaling innovations toward commercial success. The company trades on the Nasdaq Stockholm under the ticker KDEV.ST. This comprehensive approach situates Karolinska Development as a specialized investment and development entity within Nordic life sciences, combining financial capital with industry expertise, scientific access, and robust partnerships to advance medical innovations with significant patient impact and commercial potential. Its recent capital raising and planned rebranding signal a continued commitment to portfolio growth and innovation commercialization.
Company News
The subscription period in Karolinska Development AB (publ)’s rights issue begins today
Idag inleds teckningsperioden i Karolinska Development AB (publ):s företrädesemission
Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue
Karolinska Development AB (publ) offentliggör informationsdokument med anledning av förestående företrädesemission
Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development
Karolinska Developments portföljbolag SVF Vaccines planerar notering på Nasdaq First North Premier genom ett omvänt förvärv inför accelererad vaccinutveckling